Better Therapeutics, Inc. BTTX

BTTX Company Overview

Better Therapeutics, Inc. (NASDAQ: BTTX) was a digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. The company operated within the digital health, healthcare technology, and therapeutic software industries, with a primary emphasis on behavioral medicine delivered through mobile applications. Its core strategy centered on using cognitive behavioral therapy and other behavioral interventions to address underlying lifestyle factors associated with chronic diseases such as type 2 diabetes, hypertension, and related metabolic conditions.

The company’s principal product candidate and commercial asset was BT-001, a prescription digital therapeutic designed for adults with type 2 diabetes. Better Therapeutics positioned itself as an evidence-based healthcare technology company seeking regulatory validation through clinical trials and U.S. Food and Drug Administration authorization pathways. The company evolved from a broader wellness and behavioral health focus into a regulated prescription digital therapeutics model after its founding in 2015. Better Therapeutics became publicly traded through a merger with a special purpose acquisition company in 2021. Public disclosures and market filings later indicated significant financial distress, and available public records show the company substantially reduced operations and pursued strategic alternatives. Data regarding ongoing commercial activity is inconclusive based on available public sources.